Skip to main content
. Author manuscript; available in PMC: 2012 Aug 15.
Published in final edited form as: Cancer Res. 2012 Jan 5;72(4):854–864. doi: 10.1158/0008-5472.CAN-11-2795

Figure 1.

Figure 1

13C MR spectra acquired from LoVo (A-C) and HT29 (B-D) tumors and the apparent rate constant for two site exchange, kP, following intravenous administration of hyperpolarized [1-13C]pyruvate. Sequential spectra were acquired from a 6-mm tumor slice over 180s in untreated animals (left), then at 24h (center) and 72h (right), which are 24h after the first and second doses of Bevacizumab respectively. Exchange of hyperpolarized 13C label is observed between [1-13C]pyruvate (172.9ppm) and [1-13C]lactate (185.1ppm).